MAQUET Cardiovascular Receives European CE Mark For CARDIOROOT Aortic Graft

MAQUET Cardiovascular today announced that it has received European CE Mark approval for its CARDIOROOT aortic graft. An innovative, one-piece design, aortic root graft, CARDIOROOT will be used by vascular and cardiovascular surgeons to surgically repair or replace diseased and damaged aortae. It is expected to be commercially available in the EU within the next 60 days.

The distinctive design of CARDIOROOT mimics the anatomy of the patient's native aortic root, including the clinically important natural sinuses of valsalva, which supply blood to the heart's own arteries. CARDIOROOT's anatomically correct shape allows easy sewing of valve remnants or a prosthetic valve within the tube, thereby avoiding potential bleeding while shortening surgical procedure time.

"The unique concept of MAQUET CARDIOROOT combines excellent suturability with uncompromised handling. Not only is it easier to implant, but its unique uncrimped shape perfectly matches the aortic root anatomy," said Nicolas Bischoff, M.D., Head of Thoracic and Cardiovascular Surgery at Centre Hospitalier Mulhouse, France.

"We are pleased that the European authorities have approved the use of CARDIOROOT and look forward to commercializing this innovative graft in Europe," said Brad Cilley, Vice President of Marketing for MAQUET Cardiovascular. "CARDIOROOT has the outstanding handling and suturability that are the hallmarks of MAQUET surgical grafts, which are used every day in the EU in life-saving procedures. The introduction of CARDIOROOT continues MAQUET Cardiovascular's longstanding tradition of providing innovative surgical grafts to cardiothoracic and vascular surgeons to benefit their patients."

MAQUET's Portfolio of Vascular Grafts 

All MAQUET vascular grafts are designed for optimal patient outcomes and feature technologies to improve hemostasis, encourage tissue in-growth, promote natural healing and provide long-term durability.

The CARDIOROOT aortic graft is the latest addition to MAQUET Cardiovascular's portfolio of market-leading surgical grafts, which includes the HEMASHIELD line of aortic grafts, the most used and most studied vascular grafts in the world cardiothoracic surgical market. More than 2 million HEMASHIELD grafts have been implanted in patients worldwide, with clearly demonstrated clinical efficacy and improved outcomes. MAQUET's INTERGARD grafts include the innovative INTERGARD Knitted grafts with reverse Locknit construction to resist postoperative dilatation, the INTERGARD ULTRATHIN heparin-coated graft, designed to promote graft patency, and INTERGARD SILVER, the world's first antimicrobial surgical graft.

Source:
MAQUET Cardiovascular

MAQUET Cardiovascular Receives European CE Mark For CARDIOROOT Aortic Graft

MAQUET Cardiovascular today announced that it has received European CE Mark approval for its CARDIOROOT aortic graft. An innovative, one piece design, aortic root graft, CARDIOROOT will be used by vascular and cardiovascular surgeons to surgically repair or replace diseased
Industry News
2011-05-19T04:00:00Z

Comments